These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 16547501)

  • 1. Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
    Mitra SK; Lim ST; Chi A; Schlaepfer DD
    Oncogene; 2006 Jul; 25(32):4429-40. PubMed ID: 16547501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
    Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
    J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.
    Mi Z; Guo H; Wai PY; Gao C; Kuo PC
    Carcinogenesis; 2006 Jun; 27(6):1134-45. PubMed ID: 16474180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors.
    Mitra SK; Mikolon D; Molina JE; Hsia DA; Hanson DA; Chi A; Lim ST; Bernard-Trifilo JA; Ilic D; Stupack DG; Cheresh DA; Schlaepfer DD
    Oncogene; 2006 Sep; 25(44):5969-84. PubMed ID: 16682956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
    Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
    Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor growth inhibition by synthetic and expressed siRNA targeting focal adhesion kinase.
    Tsutsumi K; Kasaoka T; Park HM; Nishiyama H; Nakajima M; Honda T
    Int J Oncol; 2008 Jul; 33(1):215-24. PubMed ID: 18575768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation.
    van Nimwegen MJ; Verkoeijen S; van Buren L; Burg D; van de Water B
    Cancer Res; 2005 Jun; 65(11):4698-706. PubMed ID: 15930288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
    Kobayashi H; Gotoh J; Shinohara H; Moniwa N; Terao T
    Thromb Haemost; 1994 Apr; 71(4):474-80. PubMed ID: 8052966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice.
    Ling X; Arlinghaus RB
    Cancer Res; 2005 Apr; 65(7):2532-6. PubMed ID: 15805244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
    Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
    Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinoic acid priming potentiates the induction of urokinase-type plasminogen activator by cyclic adenosine monophosphate in mouse mammary carcinoma cells.
    Mira-y-Lopez R
    J Cell Physiol; 1991 Apr; 147(1):46-54. PubMed ID: 1645361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma.
    Todaro LB; Ladeda V; Bal de Kier Joffé E; Farías EF
    Oncol Rep; 2003; 10(3):725-32. PubMed ID: 12684650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
    Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
    Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression.
    Fayard B; Bianchi F; Dey J; Moreno E; Djaffer S; Hynes NE; Monard D
    Cancer Res; 2009 Jul; 69(14):5690-8. PubMed ID: 19584287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
    Frandsen TL; Holst-Hansen C; Nielsen BS; Christensen IJ; Nyengaard JR; Carmeliet P; Brünner N
    Cancer Res; 2001 Jan; 61(2):532-7. PubMed ID: 11212246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
    Behmoaram E; Bijian K; Jie S; Xu Y; Darnel A; Bismar TA; Alaoui-Jamali MA
    Am J Pathol; 2008 Nov; 173(5):1540-50. PubMed ID: 18832579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
    Li XF; Yan PJ; Shao ZM
    Oncogene; 2009 Nov; 28(44):3937-48. PubMed ID: 19701247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells.
    Simeone AM; Nieves-Alicea R; McMurtry VC; Colella S; Krahe R; Tari AM
    Int J Oncol; 2007 Apr; 30(4):785-92. PubMed ID: 17332916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.